in which they described the clinical course of a patient with metastatic melanoma and 10 brain metastases which were treated with SRS with complete response (including untreated lesions), was then started on BRAF/MEK inhibitors and subsequently required other treatment modalities as new metastases occurred (93). The gene discussed is BRAF; the disease is metastatic melanoma.